Literature DB >> 15475985

The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic.

Kerry Sexton1, Diana Lennon, Philipp Oster, Sue Crengle, Diana Martin, Kim Mulholland, Teuila Percival, Stewart Reid, Joanna Stewart, Jane O'Hallahan.   

Abstract

The New Zealand Meningococcal Vaccine Strategy aims to end the devastating 14-year epidemic of B:4:P1.7b,4 group B meningococcal disease in New Zealand through a mass immunisation programme to all under 20 year olds using a tailor-made vaccine (MeNZB). This paper describes the scientific rationale, development, and key components of the New Zealand Meningococcal Vaccine Strategy. A summary of the efficacy and safety data of existing outer membrane vesicle group B meningococcal vaccines is included as these data critically support the Strategy.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15475985

Source DB:  PubMed          Journal:  N Z Med J        ISSN： 0028-8446


  11 in total

1.  Cellular Immune Responses in Humans Induced by Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines Given Separately and in Combination.

Authors:  Fredrik Oftung; Gro Ellen Korsvold; Audun Aase; Lisbeth M Næss
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

2.  Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic.

Authors:  Ingeborg S Aaberge; Philipp Oster; Oddveig S Helland; Anne-Cathrine Kristoffersen; Ellen Ypma; E Arne Høiby; Berit Feiring; Hanne Nøkleby
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

3.  The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.

Authors:  D R Martin; N Ruijne; L McCallum; J O'Hallahan; P Oster
Journal:  Clin Vaccine Immunol       Date:  2006-04

4.  Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens.

Authors:  Jamie Hosking; Kumanan Rasanathan; Florina Chan Mow; Catherine Jackson; Diana Martin; Jane O'Hallahan; Philipp Oster; Ellen Ypma; Stewart Reid; Ingeborg Aaberge; Sue Crengle; Joanna Stewart; Diana Lennon
Journal:  Clin Vaccine Immunol       Date:  2007-09-26

5.  Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales.

Authors:  Jay Lucidarme; Maurizio Comanducci; Jamie Findlow; Stephen J Gray; Edward B Kaczmarski; Malcolm Guiver; Elisabeth Kugelberg; Pamela J Vallely; Philipp Oster; Mariagrazia Pizza; Stefania Bambini; Alessandro Muzzi; Christoph M Tang; Ray Borrow
Journal:  J Clin Microbiol       Date:  2009-09-16       Impact factor: 5.948

6.  Biogenesis of bacterial membrane vesicles.

Authors:  Brooke L Deatherage; J Cano Lara; Tessa Bergsbaken; Sara L Rassoulian Barrett; Stephanie Lara; Brad T Cookson
Journal:  Mol Microbiol       Date:  2009-05-08       Impact factor: 3.501

7.  Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.

Authors:  Synne Sandbu; Berit Feiring; Philipp Oster; Oddveig S Helland; Hilde S W Bakke; Lisbeth M Naess; Audun Aase; Ingeborg S Aaberge; Anne-Cathrine Kristoffersen; Kjersti M Rydland; Sandrine Tilman; Hanne Nøkleby; Einar Rosenqvist
Journal:  Clin Vaccine Immunol       Date:  2007-07-18

Review 8.  Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.

Authors:  Johan Holst; Philipp Oster; Richard Arnold; Michael V Tatley; Lisbeth M Næss; Ingeborg S Aaberge; Yvonne Galloway; Anne McNicholas; Jane O'Hallahan; Einar Rosenqvist; Steven Black
Journal:  Hum Vaccin Immunother       Date:  2013-03-07       Impact factor: 3.452

9.  Intranasal immunization with nontypeable Haemophilus influenzae outer membrane vesicles induces cross-protective immunity in mice.

Authors:  Sandro Roier; Deborah R Leitner; Jeremy Iwashkiw; Kristina Schild-Prüfert; Mario F Feldman; Georg Krohne; Joachim Reidl; Stefan Schild
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

10.  An assessment of the use of Hepatitis B Virus core protein virus-like particles to display heterologous antigens from Neisseria meningitidis.

Authors:  Sebastian Aston-Deaville; Emil Carlsson; Muhammad Saleem; Angela Thistlethwaite; Hannah Chan; Sunil Maharjan; Alessandra Facchetti; Ian M Feavers; C Alistair Siebert; Richard F Collins; Alan Roseman; Jeremy P Derrick
Journal:  Vaccine       Date:  2020-03-13       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.